Aaron Sihota
Research Subjects
Aaron Sihota has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Ahmad Chehade
UPharmacy
2 shared publicationsCameron Bonell
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia
2 shared publicationsCarolyn Whiskin
Charlton Health Inc
2 shared publicationsMichael Kani
PharmAssess Diagnostics and Custom Health, Calgary, Alberta
2 shared publicationsPavithra Ravinatarajan
Pavithra Consulting Inc., Mississauga, Ontario
2 shared publications- Alexander Chin
Department of Biological Sciences, University of Maryland, Baltimore County, Baltimore, MD
1 shared publication
Latest Publications
- Open Access
- 8 May 2026
- Published by Frontiers Media SA in Journal of Pharmacy & Pharmaceutical Sciences
- Vol. 29, 16026
Practical considerations for managing patients being treated with topical roflumilast
Topical roflumilast, available in 0.3% cream, 0.15% cream, and 0.3% foam formulations, is a novel, highly potent phosphodiesterase-4 (PDE4) inhibitor that was recently approved in Canada for the treatment of plaque psoriasis, atopic dermatitis, and seborrheic dermatitis, respectively. Topical formulations were shown in clinical trials to significantly improve disease symptoms with excellent tolerability and minimal adverse events. An oral form of roflumilast has also been approved in Canada since 2010 for the maintenance treatment of chronic obstructive pulmonary disease. The product monograph for topical roflumilast currently references a substantial amount of safety information specific to the oral formulation due to a lack of long-term safety data. Furthermore, no formal drug-drug interaction studies have been conducted with topical roflumilast, nor in special populations in whom oral roflumilast is contraindicated. Due to the impact that the route of administration has on the pharmacokinetic profile of a drug and its subsequent ability to produce undesirable or toxic effects, this presents a challenge for pharmacists who are tasked with determining how to best interpret and communicate this safety information to patients. This paper reviews the safety information contained within the product monograph for topical roflumilast in the context of the pharmacokinetic differences between the topical and oral formulations. The impact of the route of administration on adverse effect risk, drug-drug interactions, and contraindications is highlighted, and practical guidance is provided to assist pharmacists in interpreting and applying this information in practice.
- 8 May 2026
- Published by Frontiers Media SA in Journal of Pharmacy & Pharmaceutical Sciences
- Vol. 29, 16026
Open AccessPractical considerations for managing patients being treated with topical roflumilast
Topical roflumilast, available in 0.3% cream, 0.15% cream, and 0.3% foam formulations, is a novel, highly potent phosphodiesterase-4 (PDE4) inhibitor that was recently approved in Canada for the treatment of plaque psoriasis, atopic dermatitis, and seborrheic dermatitis, respectively. Topical formulations were shown in clinical trials to significantly improve disease symptoms with excellent tolerability and minimal adverse events. An oral form of roflumilast has also been approved in Canada since 2010 for the maintenance treatment of chronic obstructive pulmonary disease. The product monograph for topical roflumilast currently references a substantial amount of safety information specific to the oral formulation due to a lack of long-term safety data. Furthermore, no formal drug-drug interaction studies have been conducted with topical roflumilast, nor in special populations in whom oral roflumilast is contraindicated. Due to the impact that the route of administration has on the pharmacokinetic profile of a drug and its subsequent ability to produce undesirable or toxic effects, this presents a challenge for pharmacists who are tasked with determining how to best interpret and communicate this safety information to patients. This paper reviews the safety information contained within the product monograph for topical roflumilast in the context of the pharmacokinetic differences between the topical and oral formulations. The impact of the route of administration on adverse effect risk, drug-drug interactions, and contraindications is highlighted, and practical guidance is provided to assist pharmacists in interpreting and applying this information in practice.
- Open Access
- 30 July 2024
- Published by University of Toronto Press Inc. (UTPress) in Canadian Pharmacists Journal / Revue des Pharmaciens du Canada
- Vol. 157 (5) , 209-217
A future-forward influenza immunization model of care for high-risk patients in pharmacies: A Canadian consensus
- 30 July 2024
- Published by University of Toronto Press Inc. (UTPress) in Canadian Pharmacists Journal / Revue des Pharmaciens du Canada
- Vol. 157 (5) , 209-217
Open AccessA future-forward influenza immunization model of care for high-risk patients in pharmacies: A Canadian consensus
- 3 October 2023
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 39 (10) , S136-S137
IMPLEMENTING A MULTIDISCIPLINARY MODEL OF CGM CARE IN REAL-WORLD PHARMACY PRACTICE: A CLINICAL CONSENSUS FOR CANADIAN PHARMACISTS
- 3 October 2023
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 39 (10) , S136-S137
IMPLEMENTING A MULTIDISCIPLINARY MODEL OF CGM CARE IN REAL-WORLD PHARMACY PRACTICE: A CLINICAL CONSENSUS FOR CANADIAN PHARMACISTS
- Open Access
- 19 April 2023
- Published by University of Toronto Press Inc. (UTPress) in Canadian Pharmacists Journal / Revue des Pharmaciens du Canada
- Vol. 156 (3) , 128-136
SARS-CoV-2 rapid diagnostic testing: Canadian consensus guidance for pharmacists
- 19 April 2023
- Published by University of Toronto Press Inc. (UTPress) in Canadian Pharmacists Journal / Revue des Pharmaciens du Canada
- Vol. 156 (3) , 128-136
Open AccessSARS-CoV-2 rapid diagnostic testing: Canadian consensus guidance for pharmacists
- Open Access
- 31 July 2021
- Published by Centro de Investigaciones y Publicaciones Farmaceuticas (CIPF) in Pharmacy Practice
- Vol. 19 (3) , 2377
Monitoring the transition of patients on biologics in rheumatoid arthritis: Consensus guidance for pharmacists
Background: Recent approvals for novel agents such as the small molecule Janus kinase inhibitors (JAKi), combined with the advent of biosimilars has widened the gamut of available therapeutic options in the treatment of rheumatoid arthritis (RA). This combined with the introduction of mandatory non- medical switches to biosimilars in some jurisdictions by both public and private payors has led to a significant increase in the volume of therapeutic changes for patients. Pharmacists are well positioned to ensure effective and safe transitions, however there is a significant unmet need for objective and subjective clinical guidance around therapy as well disease state monitoring in RA that facilitates best practices throughout the patient journey. Objective: In this paper we aim to create a consensus derived monitoring algorithm for pharmacists to facilitate best practices throughout therapeutic transitions from originator biologic to other originator biologics, biosimilars, and Janus kinase inhibitors in RA. Methods: The Nominal Group Technique (NGT) was used to understand if consensus could be found among the participants. Clinically relevant questions were developed to capture solutions to the identified unmet need. The faculty considered the questions as individuals, and privately generated answers/ideas. After discussion and consideration, the participants ranked the ideas and established a consensus. Results: Based on the outcome of the consensus discussions, an algorithm was created to help guide pharmacists through therapeutic transitions in RA. The tool covers important topics such as pre-transition considerations, avoiding the nocebo effect for biosimilars, specific considerations for each drug or class, monitoring efficacy, and when to refer. Conclusions: New classes of anti-rheumatic drugs including JAKi, along with the introduction of biosimilars are presenting more opportunity for therapeutic changes and monitoring in patients with RA. We hope our evidence-based consensus derived guidance tool will assist frontline pharmacists in supporting their patients to a successful therapeutic transition in RA.
- 31 July 2021
- Published by Centro de Investigaciones y Publicaciones Farmaceuticas (CIPF) in Pharmacy Practice
- Vol. 19 (3) , 2377
Open AccessMonitoring the transition of patients on biologics in rheumatoid arthritis: Consensus guidance for pharmacists
Background: Recent approvals for novel agents such as the small molecule Janus kinase inhibitors (JAKi), combined with the advent of biosimilars has widened the gamut of available therapeutic options in the treatment of rheumatoid arthritis (RA). This combined with the introduction of mandatory non- medical switches to biosimilars in some jurisdictions by both public and private payors has led to a significant increase in the volume of therapeutic changes for patients. Pharmacists are well positioned to ensure effective and safe transitions, however there is a significant unmet need for objective and subjective clinical guidance around therapy as well disease state monitoring in RA that facilitates best practices throughout the patient journey. Objective: In this paper we aim to create a consensus derived monitoring algorithm for pharmacists to facilitate best practices throughout therapeutic transitions from originator biologic to other originator biologics, biosimilars, and Janus kinase inhibitors in RA. Methods: The Nominal Group Technique (NGT) was used to understand if consensus could be found among the participants. Clinically relevant questions were developed to capture solutions to the identified unmet need. The faculty considered the questions as individuals, and privately generated answers/ideas. After discussion and consideration, the participants ranked the ideas and established a consensus. Results: Based on the outcome of the consensus discussions, an algorithm was created to help guide pharmacists through therapeutic transitions in RA. The tool covers important topics such as pre-transition considerations, avoiding the nocebo effect for biosimilars, specific considerations for each drug or class, monitoring efficacy, and when to refer. Conclusions: New classes of anti-rheumatic drugs including JAKi, along with the introduction of biosimilars are presenting more opportunity for therapeutic changes and monitoring in patients with RA. We hope our evidence-based consensus derived guidance tool will assist frontline pharmacists in supporting their patients to a successful therapeutic transition in RA.